MA53665B1 - Agonistes du récepteur farnésoïde x et leurs utilisations - Google Patents

Agonistes du récepteur farnésoïde x et leurs utilisations

Info

Publication number
MA53665B1
MA53665B1 MA53665A MA53665A MA53665B1 MA 53665 B1 MA53665 B1 MA 53665B1 MA 53665 A MA53665 A MA 53665A MA 53665 A MA53665 A MA 53665A MA 53665 B1 MA53665 B1 MA 53665B1
Authority
MA
Morocco
Prior art keywords
farnesoid
receptor agonists
compounds
methods
receptor
Prior art date
Application number
MA53665A
Other languages
English (en)
Other versions
MA53665A (fr
Inventor
Nicholas D. Smith
Steven P. Govek
Karensa L. Douglas
Andiliy G. Lai
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of MA53665A publication Critical patent/MA53665A/fr
Publication of MA53665B1 publication Critical patent/MA53665B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Biotechnology (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne des composés qui sont des agonistes du récepteur farnésoïde X, des procédés de fabrication de tels composés, des compositions pharmaceutiques et des médicaments comprenant de tels composés, et des méthodes d'utilisation de tels composés dans le traitement d'états, de maladies ou de troubles associés à l'activité du récepteur farnésoïde X.
MA53665A 2018-09-18 2019-09-17 Agonistes du récepteur farnésoïde x et leurs utilisations MA53665B1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862733004P 2018-09-18 2018-09-18
US201862733006P 2018-09-18 2018-09-18
US201962881560P 2019-08-01 2019-08-01
PCT/US2019/051603 WO2020061113A1 (fr) 2018-09-18 2019-09-17 Agonistes du récepteur farnésoïde x et leurs utilisations
EP19862391.0A EP3852748B1 (fr) 2018-09-18 2019-09-17 Agonistes du récepteur farnésoïde x et leurs utilisations

Publications (2)

Publication Number Publication Date
MA53665A MA53665A (fr) 2021-07-28
MA53665B1 true MA53665B1 (fr) 2025-09-30

Family

ID=69887982

Family Applications (1)

Application Number Title Priority Date Filing Date
MA53665A MA53665B1 (fr) 2018-09-18 2019-09-17 Agonistes du récepteur farnésoïde x et leurs utilisations

Country Status (27)

Country Link
US (4) US11084817B2 (fr)
EP (2) EP3852748B1 (fr)
JP (1) JP7554739B2 (fr)
KR (2) KR102810978B1 (fr)
CN (1) CN113056271B (fr)
AU (2) AU2019344903B2 (fr)
BR (1) BR112021004919A2 (fr)
CA (1) CA3112411A1 (fr)
CL (1) CL2021000632A1 (fr)
DK (1) DK3852748T3 (fr)
ES (1) ES3051007T3 (fr)
FI (1) FI3852748T3 (fr)
HR (1) HRP20251321T1 (fr)
IL (1) IL281475B2 (fr)
LT (1) LT3852748T (fr)
MA (1) MA53665B1 (fr)
MD (1) MD3852748T2 (fr)
MX (1) MX2021003110A (fr)
PH (1) PH12021550605A1 (fr)
PL (1) PL3852748T3 (fr)
PT (1) PT3852748T (fr)
RS (1) RS67371B1 (fr)
SG (1) SG11202102651SA (fr)
SI (1) SI3852748T1 (fr)
SM (1) SMT202600076T1 (fr)
TW (1) TWI833805B (fr)
WO (1) WO2020061113A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7174709B2 (ja) 2017-03-15 2022-11-17 メタクリン，インク． ファルネソイドｘ受容体アゴニストおよびその使用
HRP20251322T1 (hr) * 2017-03-15 2025-12-05 Eli Lilly And Company Agonisti receptora farnesoid x i njihova upotreba
HRP20251321T1 (hr) 2018-09-18 2025-12-05 Eli Lilly And Company Agonisti farnezoid x receptora i njihova primjena
WO2021144330A1 (fr) 2020-01-15 2021-07-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Utilisation d'agonistes de fxr pour traiter une infection par le virus de l'hépatite d
CA3171987A1 (fr) * 2020-03-18 2021-09-23 Nicholas D. Smith Formes cristallines d'un agoniste du recepteur farnesoide x
WO2021188695A1 (fr) * 2020-03-18 2021-09-23 Metacrine, Inc. Formulations d'un agoniste du récepteur farnésoïde x
CA3172205A1 (fr) * 2020-03-18 2021-09-23 Metacrine, Inc. Agonistes du recepteur de farnesoide x pour le traitement d'une maladie
JP2024502673A (ja) 2021-01-14 2024-01-22 ウエヌイグレックオ・ファーマ Ｈｂｖ感染の処置のためのｆｘｒアゴニストとｉｆｎの相乗効果
JP2024517181A (ja) 2021-04-28 2024-04-19 ウエヌイグレックオ・ファーマ 組合せ治療としてｆｘｒアゴニストを使用するｔｌｒ３アゴニストの効果の強い増強
CN116554121A (zh) * 2023-05-05 2023-08-08 济南悟通生物科技有限公司 一种2-异丁基噻唑的合成方法

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL352367A1 (en) 1999-05-17 2003-08-25 Novo Nordisk As Glucagon antagonists/inverse agonists
CA2372887A1 (fr) 1999-05-25 2000-11-30 Sepracor Inc. Composes heterocycliques analgesiques et procedes d'utilisation de ces derniers
US6511980B2 (en) 2000-05-05 2003-01-28 Ortho Mcneil Pharmaceutical, Inc. Substituted diamine derivatives useful as motilin antagonists
WO2001092226A1 (fr) 2000-05-25 2001-12-06 Sepracor, Inc. Composes analgesiques heterocycliques et technique d'utilisation de ceux-ci
CA2423315A1 (fr) 2000-09-25 2002-03-28 Solange Meyer Amino-aza-cycloalcanes substitues utiles contre la malaria
FR2815032B1 (fr) 2000-10-10 2003-08-08 Pf Medicament Nouveaux derives d'aminophenyle piperazine ou d'amino phenyle piperide inhibiteurs de proteines prenyl transferase ainsi que leurs preparations
FR2825706B1 (fr) 2001-06-06 2003-12-12 Pf Medicament Nouveaux derives de benzothienyle ou d'indole, leur preparation et leur utilisation comme inhibiteurs de proteines prenyl transferase
FR2839974B1 (fr) 2002-05-24 2004-07-16 Pf Medicament Derives de phenyl-furane ou de phenyl-thiophene,leur preparation et leur application a titre de medicament
AU2003249983A1 (en) 2002-07-18 2004-02-09 Actelion Pharmaceuticals Ltd Piperidines useful for the treatment of central nervous system disorders
WO2004026823A1 (fr) 2002-09-20 2004-04-01 Pfizer Products Inc. Ligands d'amides et de sulfonamides du recepteur oestrogenique
WO2004046162A2 (fr) 2002-11-14 2004-06-03 The Scripps Research Institute Agonistes fxr non steroidiques
US20050143449A1 (en) 2002-11-15 2005-06-30 The Salk Institute For Biological Studies Non-steroidal farnesoid X receptor modulators and methods for the use thereof
US7647217B2 (en) 2002-11-15 2010-01-12 The Salk Institute For Biological Studies Structure of the farnesoid X receptor ligand binding domain and methods of use therefor
GB0309781D0 (en) 2003-04-29 2003-06-04 Glaxo Group Ltd Compounds
EP2316827B1 (fr) 2003-07-30 2016-01-27 Xenon Pharmaceuticals Inc. Derives de piperazine et leurs utilisations en tant qu'agents therapeutiques
US7754711B2 (en) 2003-07-30 2010-07-13 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
US7759348B2 (en) 2003-07-30 2010-07-20 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
WO2005058822A1 (fr) 2003-12-17 2005-06-30 Actelion Pharmaceuticals Ltd Cycloalcanes amines substitues
EP1740556A1 (fr) 2004-03-26 2007-01-10 Rigel Pharmaceuticals, Inc. Composes antiviraux heterocycliques comportant des groupes fonctionnels metabolisables et leurs utilisations
US20050272784A1 (en) 2004-05-07 2005-12-08 Xiaobing Li Inhibitors of bacterial Type III protein secretion systems
JP2006199656A (ja) 2005-01-24 2006-08-03 Kowa Co アミド基を有する環状アミン化合物
MY144229A (en) 2006-01-26 2011-08-15 Xenon Pharmaceuticals Inc Pyridazine derivatives and their use as therapeutic agents
AU2007229637A1 (en) 2006-03-28 2007-10-04 Novartis Ag Amide derivatives and their application for the treatment of G protein related diseases
US20080081824A1 (en) 2006-09-29 2008-04-03 Bristol-Myers Squibb Company Substituted piperidines as modulators of chemokine receptor activity
WO2008065500A2 (fr) 2006-11-30 2008-06-05 Pfizer Products Inc. Hétéroaryl amides comme inhibiteurs du transport de la glycine de type i
EP2234977A4 (fr) 2007-12-19 2011-04-13 Boehringer Ingelheim Int Inhibiteurs de polymérase virale
WO2010001869A1 (fr) 2008-06-30 2010-01-07 武田薬品工業株式会社 Composé de benzène tétrasubstitué et son utilisation
JP2010077109A (ja) 2008-08-28 2010-04-08 Takeda Chem Ind Ltd 複素環化合物およびその用途
CA2766874A1 (fr) 2009-07-15 2011-01-20 Stefano Crosignani Derives de tetrazole
CA2767089A1 (fr) 2009-07-15 2011-01-20 Abbott Laboratories Pyrrolopyridines inhibiteurs de kinases
FR2963005B1 (fr) 2010-07-23 2012-08-17 Sanofi Aventis Derives d'oxadiazoles et de pyridazines, leur preparation et leur application en therapeutique
KR101991326B1 (ko) 2011-03-23 2019-06-20 트레베나, 인코포레이티드. 오피오이드 수용체 리간드와 그 용도 및 제조방법
EP2545964A1 (fr) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Nouveaux composés se liant au fxr (nr1 h4) et modulant son activité
EP2732871A4 (fr) 2011-07-13 2015-03-04 M Tech Co Ltd Procédé de fabrication de microparticules avec diamètre de cristallites régulé
RU2543485C2 (ru) 2013-02-26 2015-03-10 Андрей Александрович Иващенко Гетероциклические агонисты рецепторов желчных кислот tgr5, фармацевтическая композиция, способы их получения и применения
GB201316824D0 (en) 2013-09-23 2013-11-06 R & D Vernalis Ltd New Chemical Entities
US20150258052A1 (en) 2014-03-13 2015-09-17 Salk Institute For Biological Studies Methods of using fexaramine and agents that increase sympathetic nervous system activity to promote browning of white adipose tissue
AU2015229055B2 (en) 2014-03-13 2019-09-12 Salk Institute For Biological Studies Analogs of fexaramine and methods of making and using
US10301268B2 (en) 2014-03-13 2019-05-28 The Salk Institute For Biological Studies Analogs of fexaramine and methods of making and using
US10077268B2 (en) 2014-03-13 2018-09-18 Salk Institute For Biological Studies FXR agonists and methods for making and using
JP2017510572A (ja) 2014-03-13 2017-04-13 ソーク インスティチュート フォー バイオロジカル スタディーズ Ｆｘｒアゴニストならびに作製および使用のための方法
WO2016116054A1 (fr) 2015-01-22 2016-07-28 Xiamen University Modulateurs du récepteur farnésoïde x et leurs méthodes d'utilisation
AU2016233579A1 (en) 2015-03-13 2017-10-12 Salk Institute For Biological Studies Treating latent autoimmune diabetes of adults with farnesoid X receptor agonists to activate intestinal receptors
WO2017018751A1 (fr) 2015-07-24 2017-02-02 동국대학교 산학협력단 Nouveau composé présentant une activité inhibitrice de blt et composition, destiné à prévenir ou à traiter des maladies inflammatoires, contenant ce dernier en tant que principe actif
JP6905530B2 (ja) 2015-09-16 2021-07-21 メタクリン，インク． ファルネソイドｘ受容体アゴニストとその使用
WO2017049177A1 (fr) * 2015-09-16 2017-03-23 Metacrine, Inc. Agonistes du récepteur x farnésoïde et leurs utilisations
EP3350164A4 (fr) 2015-09-16 2019-03-27 Metacrine, Inc. Agonistes du récepteur x farnésoïde et leurs utilisations
WO2017049172A1 (fr) 2015-09-16 2017-03-23 Metacrine, Inc. Agonistes du récepteur x farnésoïde et leurs utilisations
CN105477636B (zh) * 2015-10-16 2019-09-17 厦门大学 使用阿维菌素及其衍生物治疗代谢疾病的方法
CN107126419B (zh) 2016-02-26 2020-06-19 石药集团中诺药业（石家庄）有限公司 一种奥贝胆酸片剂及其制备方法
KR102316645B1 (ko) 2016-03-31 2021-10-25 가부시키가이샤 아데카 감광성 조성물 및 신규 화합물
WO2018170167A1 (fr) 2017-03-15 2018-09-20 Metacrine, Inc. Agonistes du récepteur farnésoïde x et leurs utilisations
US20200131129A1 (en) 2017-03-15 2020-04-30 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
US20200131142A1 (en) 2017-03-15 2020-04-30 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
JP7174709B2 (ja) 2017-03-15 2022-11-17 メタクリン，インク． ファルネソイドｘ受容体アゴニストおよびその使用
HRP20251322T1 (hr) * 2017-03-15 2025-12-05 Eli Lilly And Company Agonisti receptora farnesoid x i njihova upotreba
CZ2017298A3 (cs) 2017-05-26 2018-12-05 Zentiva, K.S. Amorfní formy obeticholové kyseliny
WO2020060007A1 (fr) 2018-09-17 2020-03-26 엘지전자 주식회사 Procédé et dispositif sans fil pour gérer une session de pdu dans une communication mobile 5g
JP2022500391A (ja) 2018-09-18 2022-01-04 メタクリン，インク． ファルネソイドｘ受容体アゴニストおよびその使用
WO2020061116A1 (fr) 2018-09-18 2020-03-26 Metacrine, Inc. Agonistes du récepteur farnésoïde x et leurs utilisations
HRP20251321T1 (hr) 2018-09-18 2025-12-05 Eli Lilly And Company Agonisti farnezoid x receptora i njihova primjena
AU2019344904A1 (en) 2018-09-18 2021-04-15 Metacrine, Inc. Farnesoid X receptor agonists for the treatment of disease
WO2020061118A1 (fr) 2018-09-18 2020-03-26 Metacrine, Inc. Agonistes du récepteur farnésoïde x et leurs utilisations
SG11202102586RA (en) 2018-09-18 2021-04-29 Metacrine Inc Crystalline forms of a farnesoid x receptor agonist
EP3852736A4 (fr) 2018-09-18 2022-05-18 Metacrine, Inc. Agonistes du récepteur farnésoïde x et leurs utilisations
WO2021188695A1 (fr) 2020-03-18 2021-09-23 Metacrine, Inc. Formulations d'un agoniste du récepteur farnésoïde x
CA3171987A1 (fr) 2020-03-18 2021-09-23 Nicholas D. Smith Formes cristallines d'un agoniste du recepteur farnesoide x
CA3172205A1 (fr) 2020-03-18 2021-09-23 Metacrine, Inc. Agonistes du recepteur de farnesoide x pour le traitement d'une maladie

Also Published As

Publication number Publication date
BR112021004919A2 (pt) 2021-06-01
CL2021000632A1 (es) 2021-07-23
ES3051007T3 (en) 2025-12-23
US20200102308A1 (en) 2020-04-02
IL281475B2 (en) 2025-04-01
SG11202102651SA (en) 2021-04-29
KR20250073553A (ko) 2025-05-27
KR20210076910A (ko) 2021-06-24
US11084817B2 (en) 2021-08-10
TWI833805B (zh) 2024-03-01
IL281475B1 (en) 2024-12-01
SI3852748T1 (sl) 2025-11-28
CN113056271B (zh) 2024-10-29
JP2022500392A (ja) 2022-01-04
AU2025203804A1 (en) 2025-06-12
CA3112411A1 (fr) 2020-03-26
CN113056271A (zh) 2021-06-29
JP7554739B2 (ja) 2024-09-20
IL281475A (en) 2021-04-29
EP4596543A3 (fr) 2025-10-15
AU2019344903B2 (en) 2025-02-27
KR102810978B1 (ko) 2025-05-23
US11773094B2 (en) 2023-10-03
US20230382913A1 (en) 2023-11-30
PL3852748T3 (pl) 2025-12-01
LT3852748T (lt) 2025-11-25
EP4596543A2 (fr) 2025-08-06
MA53665A (fr) 2021-07-28
DK3852748T3 (da) 2025-10-06
WO2020061113A1 (fr) 2020-03-26
SMT202600076T1 (it) 2026-03-09
RS67371B1 (sr) 2025-11-28
EP3852748B1 (fr) 2025-09-03
HRP20251321T1 (hr) 2025-12-05
FI3852748T3 (fi) 2025-10-22
PH12021550605A1 (en) 2021-10-04
MX2021003110A (es) 2021-05-13
TW202024052A (zh) 2020-07-01
US20250289821A1 (en) 2025-09-18
PT3852748T (pt) 2025-10-24
EP3852748A4 (fr) 2022-05-18
AU2019344903A1 (en) 2021-05-13
US20210395253A1 (en) 2021-12-23
MD3852748T2 (ro) 2026-01-31
EP3852748A1 (fr) 2021-07-28

Similar Documents

Publication Publication Date Title
MA53665B1 (fr) Agonistes du récepteur farnésoïde x et leurs utilisations
MA58049B1 (fr) Antagonistes du récepteur du sous-type 2 de la mélanocortine (mc2r) à pipéridine à double substitution gem et leurs utilisations
MA31764B1 (fr) Composés et compositions en tant que modulateurs de l'activité de gpr119
MA64509B1 (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA64121B1 (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA52288B1 (fr) Modulateurs d'enzymes de modification de méthyle, compositions et utilisations de ceux-ci
PH12019502058A1 (en) Farnesoid x receptor agonists and uses thereof
PH12022550359A1 (en) Nonpeptide somatostatin type 5 receptor agonists and uses thereof
MA46018A (fr) Activateurs d'édition du génome
MA47392B1 (fr) Bis-octahydrophénanthrène carboxamides et leurs conjugués protéiques
MA30462B1 (fr) Composes de pyridylamide antagonistes des canaux calciques de type t
MA47043B1 (fr) Composés indole carboxamides utiles comme inhibiteurs de kinase
MA30339B1 (fr) Azolopyrimidines inhibitrices de l'activite du recepteur cannabinoïde 1
MA39726A (fr) Compositions pharmaceutiques de composés thérapeutiquement actifs
MA44312A (fr) Anticorps et leurs méthodes d'utilisation
MA56019A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
MA39725B1 (fr) Compositions pharmaceutiques de composés thérapeutiquement actifs
EP3934646A4 (fr) Compositions pharmaceutiques pour le traitement de maladies ou de troubles oculaires
MA29931B1 (fr) Inhibiteurs de la proteine d'activation de la 5-lipoxygenase (flap)
EP3498279A4 (fr) Composition pharmaceutique comprenant comme principes actifs de l'amodiaquine et un médicament anti-diabète, destinée à la prévention ou le traitement du diabète
MA33419B1 (fr) Composés et compositions pour le traitement de maladies parasitaires
MA53765A1 (fr) Tubulysines et conjugués tubulysines-protéines
MA58646A1 (fr) Tubulysines et conjugués tubulysines-protéines
WO2017177024A8 (fr) Méthodes de traitement de troubles oculaires
EP3791869A4 (fr) Composition pharmaceutique de prévention ou de traitement de maladies neurodégénératives comprenant l'agent d'acétylation cox2 comme ingrédient actif